Oncopeptides gets CHMP positive opinion to expand Pepaxti
CHMP issued a positive opinion to expand Pepaxti (melflufen) for third-line multiple myeloma in the EU, removing the triple-class refractory requirement; an EC decision is expected in 30–60 days.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.